Cumberland acquires Vaprisol from Astellas Pharma US Cumberland Pharmaceuticals announced the acquisition of Vaprisol from Astellas Pharma US. Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with hyponatremia. Under the terms of the agreement, Cumberland will assume full responsibility for the product including its marketing, distribution and manufacture.
Cumberland announces approval of Caldolor injection Cumberland announced the approval of Caldolor Injection for pediatric patients six months of age and older. The approval was based on data submitted to the U.S. Food and Drug Administration (FDA) as part of a post-marketing commitment following approval of Caldolor in adults in 2009. Caldolor is the first and only injectable non-steroidal anti-inflammatory drug approved for use in pediatric patients.